Gene/environment interactions in the pathogenesis of autoimmunity: New insights on the role of Toll-like receptors

Autoimmunity Reviews

Volumn 14, Issue 11, 2015, Pages 971-983

  Gianchecchi, Elena ^a,b   Fierabracci, Alessandra ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b VisMederi Srl   (Italy)

Author keywords

Autoimmunity; Candidate autoimmune genes; Etiopathogenesis; Prevention treatment; TLR signaling pathway; Toll like receptors

Indexed keywords

BACTERIAL PROTEIN; FUNGAL PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NUCLEIC ACID; PATTERN RECOGNITION RECEPTOR; PROTOZOAL PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; VPR PROTEIN;

AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNITY; BEHCET DISEASE; COPY NUMBER VARIATION; CROHN DISEASE; ENZYME REGULATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ULCERATIVE COLITIS; VITILIGO; ANIMAL; GENETICS; IMMUNOLOGY;

ANIMALS; AUTOIMMUNITY; DNA COPY NUMBER VARIATIONS; GENE-ENVIRONMENT INTERACTION; HUMANS; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84941259750     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.07.006     Document Type: Review

References (207)

1. Thwaites R., Chamberlain G., Sacre S. Emerging role of endosomal toll-like receptors in rheumatoid arthritis. Front Immunol 2014, 5:1.
2. Hurst J., von Landenberg P. Toll-like receptors and autoimmunity. Autoimmun Rev 2008, 7:204-208.
3. Kumar H., Kawai T., Akira S. Pathogen recognition in the innate immune response. Biochem J 2009, 420:1-16.
4. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
5. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
6. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
7. Beutler B.A. TLRs and innate immunity. Blood 2009, 113:1399-1407.
8. Hashimoto C., Hudson K.L., Anderson K.V. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988, 52:269-279.
9. Lemaitre B., Nicolas E., Michaut L., Reichhart J.-M., Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86:973-983.
10. Takeda K., Akira S. TLR signaling pathways. Semin Immunol 2004, 16:3-9.
11. Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 1998, 95:588-593.
12. Kawai T., Akira S. TLR signaling. Semin Immunol 2007, 19:24-32.
13. Poltorak A., He X., Smirnova I., Liu M.Y., Huffel C.V., Du X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutation in Tlr4 gene. Science 1998, 282:2085-2088.
14. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999, 162:3749-3752.
15. Underhill D.M., Ozinsky A., Hajjar A.M., Stevens A., Wilson C.B., Bassetti M., et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999, 401:811-815.
16. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
17. Kaisho T., Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006, 117:979-987.
18. Hacker H., Vabulas R.M., Takeuchi O., Hoshino K., Akira S., Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000, 192:595-600.
19. Schnare M., Holt A.C., Takeda K., Akira S., Medzhitov R. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol 2000, 10:1139-1142.
20. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo S., Hoshino K., et al. Small antiviral compounds activate immune cells via TLR7 MyD88-dependent signalling pathway. Nat Immunol 2002, 3:196-200.
21. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor-5. Nature 2001, 410:1099-1103.
22. Suzuki N., Suzuki S., Yeh W.C. IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol 2002, 23:503-506.
23. Chen Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005, 7:758-765.
24. Janssens S., Burns K., Tschopp J., Beyaert R. Regulation of interleukin-1 and lipopolysaccharide-induced NF-κB activation by alternative splicing of MyD88. Curr Biol 2002, 12:467-471.
25. Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J. Inhibition of IL-1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003, 197:263-268.
26. Yamamoto M., Sato S., Hemmi H., Uematsu S., Hoshino K., Kaisho T., et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003, 4:1144-1150.
27. Meylan E., Burns K., Hofmann K., Blancheteau V., Martinon F., Kelliher M., et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004, 5:503-507.
28. Carty M., Goodbody R., Schroder M., Stack J., Moynagh P.N., Bowie A.G. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006, 7:1074-1081.
29. Couillault C., Pujol N., Reboul J., Sabatier L., Guichou J.F., Kohara Y., et al. TLR-independent control of innate immunity in Caenorhabditis elegans by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. Nat Immunol 2004, 5:488-494.
30. Covert M.W., Leung T.H., Gaston J.E., Baltimore D. Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 2005, 309:1854-1857.
31. Kawai T., Akira S. Innate immune recognition of viral infection. Nat Immunol 2006, 7:131-137.
32. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004, 5:730-737.
33. Lincez P.J., Shanina I., Horwitz M.S. Reduced expression of the MDA5 gene IFIH1 prevents autoimmune diabetes. Diabetes 2015, 64:2184-2193.
34. Ishii K.J., Coban C., Kato H., Takahashi K., Torii Y., Takeshita F., et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006, 7:40-48.
35. Zhang D., Zhang G., Hayden M.S., Greenblatt M.B., Bussey C., Flavell R.A., et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004, 303:1522-1526.
36. Takeuchi O., Hoshino K., Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000, 165:5392-5396.
37. Echchannaoui H., Frei K., Schnell C., Leib S.L., Zimmerli W., Landmann R. Toll-like receptor 2-deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation. J Infect Dis 2002, 186:798-806.
38. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 2004, 25:381-386.
39. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
40. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
41. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
42. Krug A., French A.R., Barchet W., Fischer J.A., Dzionek A., Pingel J.T., et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004, 21:107-119.
43. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009, 21:317-337.
44. Adachi K., Tsutsui H., Kashiwamura S., Seki E., Nakano H., Takeuchi O., et al. Plasmodium berghei infection in mice induces liver injury by an IL-12- and toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J Immunol 2001, 167:5928-5934.
45. Lee S., Kang D., Ra E.A., Lee T.A., Ploegh H.L., Park B. Negative regulation of TLR9 signaling by its N-terminal proteolytic cleavage product. J Immunol 2014, 193:3726-3735.
46. Wang Y., Tang Y., Teng L., Wu Y., Zhao X., Pei G. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2006, 7:139-147.
47. Boone D.L., Turer E.E., Lee E.G., Ahmad R.C., Wheeler M.T., Tsui C., et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004, 5:1052-1060.
48. Negishi H., Ohba Y., Yanai H., Takaoka A., Honma K., Yui K., et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A 2005, 102:15989-15994.
49. Brint E.K., Xu D., Liu H., Dunne A., McKenzie A.N., O'Neill L.A., et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004, 5:373-379.
50. Saitoh T., Tun-Kyi A., Ryo A., Yamamoto M., Finn G., Fujita T., et al. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol 2006, 7:598-605.
51. Su X., Li S., Meng M., Qian W., Xie W., Chen D., et al. TNF receptor-associated factor-1 (TRAF1) negatively regulates Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)-mediated signaling. Eur J Immunol 2006, 36:199-206.
52. Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J., et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006, 7:148-155.
53. Gilchrist M., Thorsson V., Li B., Rust A.G., Korb M., Kennedy K., et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 2006, 441:173-178.
54. Richez C., Blanco P., Rifkin I., Moreau J.F., Schaeverbeke T. Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus. Joint Bone Spine 2011, 78:124-130.
55. Bot A. In this issue: autoimmunity and innate immunity. Int Rev Immunol 2014, 33:1-2.
56. van der Laan J.W., Gould S., Tanir J.Y., Vaccines I.L.S.I.H.E.S.I., Committee Adjuvants Safety Project Safety of vaccine adjuvants: focus on autoimmunity. Vaccine 2015, 33:1507-1514.
57. Edwards A.D., Diebold S.S., Slack E.M., Tomizawa H., Hemmi H., Kaisho T., et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8alpha+DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 2003, 33:827-833.
58. Gursel I., Gursel M., Yamada H., Ishii K.J., Takeshita F., Klinman D.M. Elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol 2003, 171:1393-1400.
59. Kariko K., Buckstein M., Ni H., Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005, 23:165-175.
60. Rifkin I.R., Leadbetter E.A., Busconi L., Viglianti G., Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27-42.
61. Papadimitraki E.D., Choulaki C., Koutala E., Bertsias G., Tsatsanis C., Gergianaki I., et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006, 54:3601-3611.
62. Stechova K., Kolar M., Blatny R., Halbhuber Z., Vcelakova J., Hubackova M., et al. Healthy first degree relatives of patients with type 1 diabetes exhibit significant differences in basal gene expression pattern of immunocompetent cells compared to controls: expression pattern as predeterminant of autoimmune diabetes. Scand J Immunol 2011, 75:210-219.
63. Lee M.S. Treatment of autoimmune diabetes by inhibiting the initial event. Immune Netw 2013, 13:194-198.
64. Sun C., Zhi D., Shen S., Luo F., Sanjeevi C.B. SNPs in the exons of Toll-like receptors are associated with susceptibility to type 1 diabetes in Chinese population. Hum Immunol 2014, 75:1084-1088.
65. Zhu W., Yang W., He Z., Liao X., Wu J., Sun J., et al. Overexpressing autoimmune regulator regulates the expression of toll-like receptors by interacting with their promoters in RAW264.7 cells. Cell Immunol 2011, 270:156-163.
66. Sacre S.M., Lo A., Gregory B., Simmonds R.E., Williams L., Feldmann M., et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J Immunol 2008, 181:8002-8009.
67. Han S.W., Lee W.K., Kwon K.T., Lee B.K., Nam E.J., Kim G.W. Association of polymorphisms in interferon regulatory factor 5 gene with rheumatoid arthritis: a metaanalysis. J Rheumatol 2009, 36:693-697.
68. Enevold C., Radstake T.R., Coenen M.J., Fransen J., Toonen E.J., Bendtzen K., et al. Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritis. J Rheumatol 2010, 37:905-910.
69. Lin Y.T., Verma A., Hodgkinson C.P. Toll-like receptors and human disease: lessons from single nucleotide polymorphisms. Curr Genomics 2012, 13:633-645.
70. Davis M.L., LeVan T.D., Yu F., Sayles H., Sokolove J., Robinson W., et al. Associations of toll-like receptor (TLR)-4 single nucleotide polymorphisms and rheumatoid arthritis disease progression: an observational cohort study. Int Immunopharmacol 2015, 24:346-352.
71. García-Ortiz H., Velázquez-Cruz R., Espinosa-Rosales F., Jiménez-Morales S., Baca V., Orozco L. Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann Rheum Dis 2010, 69:1861-1865.
72. Pacheco G.V., Cruz D.C., González Herrera L.J., Pérez Mendoza G.J., Adrián Amaro G.I., Nakazawa Ueji Y.E., et al. Copy number variation of TLR-7 gene and its association with the development of systemic lupus erythematosus in female patients from Yucatan Mexico. Genet Epigenet 2014, 6:31-36.
73. Wei J., Bhattacharyya S., Tourtellotte W.G., Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011, 10:267-275.
74. Broen J.C., Bossini-Castillo L., van Bon L., Vonk M.C., Knaapen H., Beretta L., et al. A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum 2012, 64:264-271.
75. Bhattacharyya S., Kelley K., Melichian D.S., Tamaki Z., Fang F., Su Y., et al. Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013, 182:192-205.
76. Takahashi T., Asano Y., Ichimura Y., Toyama T., Taniguchi T., Noda S., et al. Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheum 2015, 67:254-265.
77. Kirino Y., Takeno M., Watanabe R., Murakami S., Kobayashi M., Ideguchi H., et al. Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behçet's disease. Arthritis Res Ther 2008, 10:R16.
78. Nara K., Kurokawa M.S., Chiba S., Yoshikawa H., Tsukikawa S., Matsuda T., et al. Involvement of innate immunity in the pathogenesis of intestinal Behçet's disease. Clin Exp Immunol 2008, 152:245-251.
79. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004, 53:987-992.
80. Shen X.Y., Shi R.H., Wang Y., Zhang H.J., Zhou X.Q., Shen F.C., et al. Toll-like receptor gene polymorphisms and susceptibility to inflammatory bowel disease in Chinese Han and Caucasian populations. Zhonghua Yi Xue Za Zhi 2010, 90:1416-1420.
81. Shen X., Shi R., Zhang H., Li K., Zhao Y., Zhang R. The Toll-like receptor 4 D299G and T399I polymorphisms are associated with Crohn's disease and ulcerative colitis: a meta-analysis. Digestion 2010, 81:69-77.
82. Ji X., Wang Y., Huang G., Zhou W. TLR3c.1377, TLR9-1486, and TLR9 2848 gene polymorphisms and multiple sclerosis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010, 35:116-122.
83. Kristjansdottir G., Sandling J.K., Bonetti A., Roos I.M., Milani L., Wang C., et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 2008, 45:362-369.
84. Karaca N., Ozturk G., Gerceker B.T., Turkmen M., Berdeli A. TLR2 and TLR4 gene polymorphisms in Turkish vitiligo patients. J Eur Acad Dermatol Venereol 2013, 27:e85-e90.
85. Wang Y.Z., Yan M., Tian F.F., Zhang J.M., Liu Q., Yang H., et al. Possible involvement of Toll-like receptors in the pathogenesis of myasthenia gravis. Inflammation 2013, 36:121-130.
86. Bernasconi P., Barberis M., Baggi F., Passerini L., Cannone M., Arnoldi E., et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005, 167:129-139.
87. Silveira P.A., Grey S.T. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol Metab 2006, 17:128-135.
88. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
89. Fierabracci A. The potential of multimer technologies in type 1 diabetes prediction strategies. Diabetes Metab Res Rev 2011, 27:216-229.
90. Gianchecchi E., Palombi M., Fierabracci A. The putative role of the C1858T polymorphism of protein tyrosine phosphatase PTPN22 gene in autoimmunity. Autoimmun Rev 2013, 12:717-725.
91. Wen L., Peng J., Li Z., Wong F.S. The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets. J Immunol 2004, 172:3173-3180.
92. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005, 11:138-145.
93. Kim H.S., Han M.S., Chung K.W., Kim S., Kim E., Kim M.J., et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 2007, 27:321-333.
94. Zipris D., Lien E., Xie J.X., Greiner D.L., Mordes J.P., Rossini A.A. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol 2005, 174:131-142.
95. Wen L., Ley R.E., Volchkov P.Y., Stranges P.B., Avanesyan L., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455:1109-3.
96. Aumeunier A., Grela F., Ramadan A., Pham Van L., Bardel E., Gomez Alcala A., et al. Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One 2010, 5. e11484.
97. Han D., Cai X., Wen J., Matheson D., Skyler J.S., Kenyon N.S., et al. Innate and adaptive immune gene expression profiles as biomarkers in human type 1 diabetes. Clin Exp Immunol 2012, 170:131-138.
98. Meyers A., Shah R., Gottlieb P., Zipris D. Altered toll-like receptor signaling pathways in human type 1 diabetes. J Mol Med 2010, 88:1221-1231.
99. Alkanani A.K., Rewers M., Dong F., Waugh K., Gottlieb P.A., Zipris D. Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes. Diabetes 2012, 61:2525-2533.
100. Kristiansen O.P., Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes 2005, 54:S114-S124.
101. Gianchecchi E., Crinò A., Giorda E., Luciano R., Perri V., Russo A.L., et al. Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis. PLoS One 2014, 9. e110755.
102. Petrich de Marquesini L.G., Fu J., Connor K.J., Bishop A.J., McLintock N.E., Pope C., et al. IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 2010, 53:1451-1460.
103. Devaraj S., Dasu M.R., Park S.H., Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009, 52:1665-1668.
104. Castiblanco J., Varela D.C., Castaño-Rodríguez N., Rojas-Villarraga A., Hincapié M.E., Anaya J.M. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008, 8:541-544.
105. Assmann T.S., Brondani Lde A., Bauer A.C., Canani L.H., Crispim D. Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. Eur J Endocrinol 2014, 170:519-527.
106. Proust-Lemoine E., Saugier-Veber P., Wémeau J.L. Polyglandular autoimmune syndrome type I. Presse Med 2012, 41:e651-e662.
107. Fierabracci A. Recent insights into the role and molecular mechanisms of the autoimmune regulator (AIRE) gene in autoimmunity. Autoimmun Rev 2011, 10:137-143.
108. Sedivá A., Ciháková D., Lebl J. Immunological findings in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and their family members: are heterozygotes subclinically affected?. J Pediatr Endocrinol Metab 2002, 15:1491-1496.
109. Hong M., Ryan K.R., Arkwright P.D., Gennery A.R., Costigan C., Dominguez M., et al. Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. Clin Exp Immunol 2009, 156:40-51.
110. Boissier M.C., Semerano L., Challal S., Saidenberg-Kermanac'h N., Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 2012, 39:222-228.
111. Meng L., Zhu W., Jiang C., He X., Hou W., Zheng F., et al. Toll-like receptor 3 upregulation in macrophages participates in the initiation and maintenance of pristane-induced arthritis in rats. Arthritis Res Ther 2010, 12:R103.
112. Zhu W., Meng L., Jiang C., Xu J., Wang B., Han Y., et al. Overexpression of toll-like receptor 3 in spleen is associated with experimental arthritis in rats. Scand J Immunol 2012, 76:263-270.
113. Yarilina A., DiCarlo E., Ivashkiv L.B. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol 2007, 178:2204-2211.
114. Hayashi T., Gray C.S., Chan M., Tawatao R.I., Ronacher L., McGargill M.A., et al. Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci U S A 2009, 106:2764-2769.
115. Alzabin S., Kong P., Medghalchi M., Palfreeman A., Williams R., Sacre S. Investigation of the role of endosomal Toll-like receptors in murine collagen-induced arthritis reveals a potential role for TLR7 in disease maintenance. Arthritis Res Ther 2012, 14:R142.
116. Chen S.Y., Shiau A.L., Li Y.T., Lin Y.S., Lee C.H., Wu C.L., et al. Suppression of collagen-induced arthritis by intra-articular lentiviral vector-mediated delivery of Toll-like receptor 7 short hairpin RNA gene. Gene Ther 2012, 19:752-760.
117. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
118. Demaria O., Pagni P.P., Traub S., de Gassart A., Branzk N., Murphy A.J., et al. TLR8 deficiency leads to autoimmunity in mice. J Clin Invest 2010, 120:3651-3662.
119. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75:330-337.
120. Wang Y., Stanford S., Zhou W., Auger Jennifer L., Cheng G., Campbell A., et al. Rheumatoid arthritis-associated PTPN22 modulates toll-like receptor-mediated, type 1 interferon-dependent innate immunoregulation. Arthritis Rheum 2012, 64:2452.
121. Zheng J., Petersen F., Yu X. The role of PTPN22 in autoimmunity: learning from mice. Autoimmun Rev 2014, 13:266-271.
122. Herman S., Fischer A., Pfatschbacher J., Hoffmann M., Steiner G. A TLR 9 antagonist diminishes arthritis severity in a rat model of rheumatoid arthritis. Ann Rheum Dis 2011, 70:A39.
123. Brentano F., Schorr O., Gay R.E., Gay S., Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005, 52:2656-2665.
124. Roelofs M.F., Joosten L.A., Abdollahi-Roodsaz S., van Lieshout A.W., Sprong T., van den Hoogen F.H., et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005, 52:2313-2322.
125. Ospelt C., Brentano F., Rengel Y., Stanczyk J., Kolling C., Tak P.P., et al. Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008, 58:3684-3692.
126. Tamaki Y., Takakubo Y., Hirayama T., Konttinen Y.T., Goodman S.B., Yamakawa M., et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol 2011, 38:810-820.
127. Kilding R., Akil M., Till S., Amos R., Winfield J., Iles M.M., et al. A biologically important single nucleotide polymorphism within the toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin Exp Rheumatol 2003, 21:340-342.
128. Radstake T.R., Franke B., Hanssen S., Netea M.G., Welsing P., Barrera P., et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum 2004, 50:999-1001.
129. Kuuliala K., Orpana A., Leirisalo-Repo M., Kautiainen H., Hurme M., Hannonen P., et al. Polymorphism at position +896 of the Toll-like receptor 4 gene interferes with rapid response to therapy in rheumatoid arthritis. Ann Rheum Dis 2006, 65:1241-1243.
130. Sanchez E., Orozco G., Lopez-Nevot M.A., Jimenez-Alonso J., Martin J. Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 2004, 63:54-57.
131. Jaen O., Petit-Teixeira E., Kirsten H., Ahnert P., Semerano L., Pierlot C., et al. No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis. Falgarone G; European Consortium on Rheumatoid Arthritis Families. Arthritis Res Ther 2009, 11:R5.
132. Laska M.J., Hansen B., Troldborg A., Lorenzen T., Stengaard-Pedersen K., Junker P., et al. A non-synonymous single-nucleotide polymorphism in the gene encoding Toll-like Receptor 3 (TLR3) is associated with sero-negative rheumatoid arthritis (RA) in a Danish population. BMC Res Notes 2014, 7:716.
133. Coenen M.J., Enevold C., Barrera P., Schijvenaars M.M., Toonen E.J., Scheffer H., et al. Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. PLoS One 2010, 5. e14326.
134. Etem E.O., Elyas H., Ozgocmen S., Yildirim A., Godekmerdan A. The investigation of toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients. Rheumatol Int 2011, 31:1369-1374.
135. Dawidowicz K., Allanore Y., Guedj M., Pierlot C., Bombardieri S., Balsa A., et al. The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype. Ann Rheum Dis 2011, 70:117-121.
136. Kim Y.J., Park J.H., Kim I., Kim J.O., Bae J.S., Shin H.D., et al. Putative role of functional interferon regulatory factor 5 (IRF5) polymorphism in rheumatoid arthritis in a Korean population. J Rheumatol 2008, 35:2106-2118.
137. Maalej A., Hamad M.B., Rebaï A., Teixeira V.H., Bahloul Z., Marzouk S., et al. Association of IRF5 gene polymorphisms with rheumatoid arthritis in a Tunisian population. Scand J Rheumatol 2008, 37:414-418.
138. Shimane K., Kochi Y., Yamada R., Okada Y., Suzuki A., Miyatake A., et al. A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population. Ann Rheum Dis 2009, 68:377-383.
139. Sacre S.M., Andreakos E., Kiriakidis S., Amjadi P., Lundberg A., Giddins G., et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 2007, 170:518-525.
140. Kotzin B.L. Systemic lupus erythematosus. Cell 1996, 85:303-306.
141. Nakano S., Morimoto S., Suzuki J., Nozawa K., Amano H., Tokano Y., et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008, 47:145-149.
142. Rahman A., Isenberg D. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939.
143. Rönnblom L., Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008, 17:394-399.
144. Robinson E.S., Werth V.P. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine 2014, 73:326-334.
145. Eichler E., Nickerson D., Altshuler D., Bowcock A., et al. Completing the map of human genetics variation. Nature 2007, 447:161-165.
146. Barrat F.J., Meeker T., Chan J.H., Guiducci C., Coffman R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007, 37:3582-3586.
147. Tabeta K., Hoebe K., Janssen E.M., Du X., Georgel P., Crozat K., et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006, 7:156-164.
148. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunol 2006, 25:417-428.
149. Santiago-Raber M.L., Kikuchi S., Borel P., Uematsu S., Akira S., Kotzin B.L., et al. Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus. J Immunol 2008, 181:1556-1562.
150. Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005, 202:321-331.
151. Kelley J., Johnson M., Alarcón G., Kimberly R., Edberg J. Variation in the relative copy number of the TLR-7 gene in patients with systemic lupus erythematosus and healthy control subjects. Arthritis Rheum 2007, 56:3375-3378.
152. Rupasree Y., Naushad S.M., Rajasekhar L., Uma A., Kutala V.K. Association of TLR4 (D299G, T399I), TLR9-1486T>C, TIRAP S180L and TNF-α promoter (-1031, -863, -857) polymorphisms with risk for systemic lupus erythematosus among South Indians. Lupus 2015, 24:50-57.
153. Devaraju P., Gulati R., Antony P.T., Mithun C.B., Negi V.S. Susceptibility to SLE in South Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Mol Immunol 2015, 64:123-126.
154. Wang C.M., Chang S.W., Wu Y.J., Lin J.C., Ho H.H., Chou T.C., et al. Genetic variations in Toll-like receptors (TLRs 3/7/8) are associated with systemic lupus erythematosus in a Taiwanese population. Sci Rep 2014, 4:3792.
155. Enevold C., Nielsen C.H., Jacobsen R.S., Hermansen M.L., Molbo D., Avlund K., et al. Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus. Mol Biol Rep 2014, 41:5755-5763.
156. Armstrong D.L., Reiff A., Myones B.L., Quismorio F.P., Klein-Gitelman M., McCurdy D., et al. Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun 2009, 10:446-456.
157. Graham R.R., Kozyrev S.V., Baechler E.C., Reddy M.V., Plenge R.M., Bauer J.W., et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006, 38:550-555.
158. Kelly J.A., Kelley J.M., Kaufman K.M., Kilpatrick J., Bruner G.R., Merrill J.T., et al. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun 2008, 9:187-194.
159. Sigurdsson S., Göring H.H., Kristjansdottir G., Milani L., Nordmark G., Sandling J.K., et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008, 17:872-881.
160. Siu H.O., Yang W., Lau C.S., Chan T.M., Wong R.W., Wong W.H., et al. Association of a haplotype of IRF5 gene with systemic lupus erythematosus in Chinese. J Rheumatol 2008, 35:360-362.
161. Elghzaly A.A., Metwally S.S., El-Chennawi F.A., Elgayaar M.A., Mosaad Y.M., El-Toraby E.E., et al. IRF5, PTPN22, CD28, IL2RA, KIF5A, BLK and TNFAIP3 genes polymorphisms and lupus susceptibility in a cohort from Delta; relation to other ethnic groups. Hum Immunol 2015 Jun 17, 10.1016/j.humimm.2015.06.001.
162. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
163. Asano Y. Future treatments in systemic sclerosis. J Dermatol 2010, 37:54-70.
164. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567.
165. Yamamoto T., Takagawa S., Katayama I., Yamazaki K., Hamazaki Y., Shinkai H., et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999, 112:456-462.
166. Lehner T. Immunopathogenesis of Behçet's disease. Ann Med Interne 1999, 150:483-487.
167. Yurdakul S., Hamuryudan V., Yazici H. Behçet syndrome. Curr Opin Rheumatol 2004, 16:38-42.
168. Karasneh J., Gül A., Ollier W.E., Silman A.J., Worthington J. Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. Arthritis Rheum 2005, 52:1836-1842.
169. Sakane T., Takeno M., Suzuki N., Inaba G. Behçet's disease. N Engl J Med 1999, 341:1284-1291.
170. Melikoglu M., Uysal S., Krueger J.G., Kaplan G., Gogus F., Yazici H., et al. Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol 2006, 177:6415-6421.
171. Takada Y., Fujita Y., Igarashi M., Katsumata T., Okabe H., Saigenji K., et al. Intestinal Behçet's disease-pathognomonic changes in intramucosal lymphoid tissues and effect of a "rest cure" on intestinal lesions. J Gastroenterol 1997, 32:598-604.
172. Gül A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001, 19:S6-S12.
173. Zierhut M., Mizuki N., Ohno S., Inoko H., Gül A., Onoé K., et al. Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 2003, 60:1903-1922.
174. Skin Anonymous, hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease: a multicenter study, The Behcet's Disease Research Committee of Japan. J Rheumatol 1989, 16:506-511.
175. Sezer F.N. The isolation of a virus as the cause of Behcet's diseases. Am J Ophthalmol 1953, 36:301-315.
176. Lee S., Bang D., Cho Y.H., Lee E.S., Sohn S. Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behcet's disease. Arch Dermatol Res 1996, 288:179-183.
177. Ohashi K., Burkart V., Flohé S., Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000, 164:558-561.
178. Vabulas R.M., Ahmad-Nejad P., da Costa C., Miethke T., Kirschning C.J., Häcker H., et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001, 276:31332-31339.
179. Poss K.D., Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci U S A 1997, 94:10925-10930.
180. Yachie A., Niida Y., Wada T., Igarashi N., Kaneda H., Toma T., et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 1999, 103:129-135.
181. Liu X., Wang C., Ye Z., Kijlstra A., Yang P. Higher expression of Toll-like receptors 2, 3, 4, and 8 in ocular Behcet's disease. Invest Ophthalmol Vis Sci 2013, 54:6012-6017.
182. Ito A., Ota M., Katsuyama Y., Inoko H., Ohno S., Mizuki N. Lack of association of Toll-like receptor 9 gene polymorphism with Behçet's disease in Japanese patients. Tissue Antigens 2007, 70:423-426.
183. Ben Dhifallah I., Lachheb J., Houman H., Hamzaoui K. Toll-like-receptor gene polymorphisms in a Tunisian population with Behçet's disease. Clin Exp Rheumatol 2009, 27:S58-S62.
184. Boiardi L., Atzeni F., Casali B., Farnetti E., Nicoli D., Pipitone N., et al. Toll-like receptor 4 (TLR4) gene polymorphisms in Italian patients with Behçet's disease. Clin Exp Rheumatol 2009, 27:S43-S47.
185. Durrani O., Banahan K., Sheedy F.J., McBride L., Ben-Chetrit E., Greiner K., et al. TIRAP Ser180Leu polymorphism is associated with Behcet's disease. Rheumatology (Oxford) 2011, 50:1760-1765.
186. Fang J., Hu R., Hou S., Xiang Q., Qi J., Zhou Y., et al. Association of TLR2 gene polymorphisms with ocular Behcet's disease in a Chinese Han population. Invest Ophthalmol Vis Sci 2013, 54:8384-8392.
187. Fang J., Chen L., Tang J., Hou S., Liao D., Ye Z., et al. Association between copy number variations of TLR7 and ocular Behçet's disease in a Chinese Han population. Invest Ophthalmol Vis Sci 2015, 56:1517-1523.
188. Geremia A., Biancheri P., Allan P., Corazza G.R., Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014, 13:3-10.
189. Browning B.L., Huebner C., Petermann I., Gearry R.B., Barclay M.L., Shelling A.N., et al. Has toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am J Gastroenterol 2007, 102:2504-2512.
190. De Jager P.L., Franchimont D., Waliszewska A., Bitton A., Cohen A., Langelier D. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007, 8:387-397.
191. Hong J., Leung E., Fraser A.G., Merriman T.R., Vishnu P., Krissansen G.W. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol 2007, 22:1760-1766.
192. Hume G.E., Fowler E.V., Doecke J., Simms L.A., Huang N., Palmieri O., et al. Novel NOD2 haplotype strengthens the association between TLR4 Asp299Gly and Crohn's disease in an Australian population. Inflamm Bowel Dis 2008, 14:585-590.
193. Abad C., González-Escribano M.F., Diaz-Gallo L.M., Lucena-Soto J.M., Márquez J.L., Leo E., et al. Association of Toll-like receptor 10 and susceptibility to Crohn's disease independent of NOD2. Genes Immun 2011, 12:635-642.
194. Morgan A.R., Lam W.J., Han D.Y., Fraser A.G., Ferguson L.R. Genetic variation within TLR10 is associated with Crohn's disease in a New Zealand population. Hum Immunol 2012, 7:416-420.
195. Meena N.K., Ahuja V., Meena K., Paul J. Association of TLR5 gene polymorphisms in ulcerative colitis patients of north India and their role in cytokine homeostasis. PLoS One 2015, 10:e0120697.
196. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 2008, 31:247-269.
197. Hasheminia S.J., Zarkesh-Esfahani S.H., Tolouei S., Shaygannejad V., Shirzad H., Hashemzadeh Chaleshtory M. Toll like receptor 2 and 4 expression in peripheral blood mononuclear cells of multiple sclerosis patients. Iran J Immunol 2014, 11:74-83.
198. Kovacs S.O. Vitiligo. J Am Acad Dermatol 1998, 38:647-666.
199. Spritz R.A. Modern vitiligo genetics sheds new light on an ancient disease. J Dermatol 2013, 40:310-318.
200. Cavalcante P., Cufi P., Mantegazza R., Berrih-Aknin S., Bernasconi P., Le Panse R. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev 2013, 12:863-874.
201. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12:875-884.
202. Ning S. Innate immune modulation in EBV infection. Herpesviridae 2011, 2:1.
203. Cufi P., Dragin N., Weiss J.M., Martinez-Martinez P., Roussin R., Berrih Aknin S., et al. Implication of dsRNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2013, 73:281-293.
204. Temajo N.O., Howard N. The mosaic of environment involvement in autoimmunity: the abrogation of viral latency by stress, a non-infectious environmental agent, is an intrinsic prerequisite prelude before viruses can rank as infectious environmental agents that trigger autoimmune diseases. Autoimmun Rev 2014, 13:635-640.
205. Zhu J., Mohan C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediators Inflamm 2010, 2010:781235.
206. Horton C.G., Pan Z.J., Farris A.D. Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm 2010, 2010.
207. Johar A.S., Anaya J.M., Andrews D., Patel H.R., Field M., Goodnow C., et al. Candidate gene discovery in autoimmunity by using extreme phenotypes, next generation sequencing and whole exome capture. Autoimmun Rev 2015, 14:204-209.